Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

million (compared to euro 7,898 million in Q1 2010, including euro 513 million for Merial). Sales were up 0.1% excluding A/H1N1 sales and despite euro 569 million of sales lost in 2011 due to generic competition versus the comparable period in 2010.
  • Merial is now fully consolidated(4); sales were up 11.5% while business operating margin reached 36.7%.
  • Growth Platforms (excluding A/H1N1 sales) grew 15.5% and contributed 59.2% of Group sales in Q1 2011 versus 51.4% in Q1 2010.
  • Emerging Markets(5) sales reached euro 2,386 million, up 14.6% (excluding A/H1N1 sales), exceeding the U.S. and Western Europe and accounted for 30.7% of Group sales.
  • Business EPS(1) was euro 1.66, down 16.1% at CER. Excluding A/H1N1 sales, decrease in business EPS(1) was limited to 6.0% at CER.
  • Free cash flow was stable at euro 2,006 million, and the Group had a positive net cash position at the end of Q1 2011 prior to the Genzyme acquisition in April.

  • Outlook

  • The Group is on track to achieve previously announced cost savings of euro 2 billion(6) per year by end of 2011.
  • Regulatory filings for 3 major late-stage pipeline projects (lixisenatide, alemtuzumab and teriflunomide) are expected in the next 12 months. Aflibercept showed positive Phase III results in second-line metastatic colorectal cancer.
  • The acquisition of Genzyme adds a new growth platform and a global center for excellence in rare diseases. This transaction is an important achievement of the Group's sustainable growth strategy.
  • Full year 2011 guidance provided earlier this year will be reviewed at half-year results.
  • (1) See Appendix 9 for definitions of financial indicators; (2) Constant Exchange Rates; (3) Growth in net sales is expressed at constant exchang
    '/>"/>

    SOURCE sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

    Related medicine technology :

    1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
    2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
    5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
    6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
    7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
    8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
    9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
    10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
    11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
    (Date:9/18/2014)... 18, 2014  A $3 million grant from The ... of Michigan to establish a national center of excellence ... for Aging Research at U-M will focus on exploiting ... the effects of aging and postpone diseases in animal ... can help develop medications that may help people live ...
    (Date:9/18/2014)... 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... and Drug Administration (FDA) has removed the clinical ... in SWOG,s ongoing Phase 1b/2 clinical trial (S1313). ... drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination ... metastatic pancreatic adenocarcinoma.  The study will resume under ...
    Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4
    (Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... patients seeking care at larger urban hospitals are likely to ... at smaller or more rural facilities, new research suggests. ... emergency care varies dramatically across hospitals in the United States," ... Renee Hsia, an associate professor at the University of California, ...
    (Date:9/18/2014)... Chest Physicians (CHEST) together with the Chinese Thoracic ... of CTS that CHEST World Congress 2016 will ... critical care, and sleep medicine from around the ... slated for spring 2016. , CHEST World ... hands-on simulation training, keynote addresses, presentations by leading ...
    (Date:9/18/2014)... September 18, 2014 Qualis Health, one ... published a white paper, “Advancing Primary Care through ... Information Technology.” , Authors Jeff Hummel, MD, MPH ... guidance to organizations engaged in the work of becoming ... IT can bolster PCMH objectives, such as generating and ...
    (Date:9/18/2014)... have developed a new method to study Ebola virus ... Wildlife Conservation Society (WCS)-led research, published today in the ... use of fecal samples from wild great apes to ... virus. This represents a new tool for performing large, ... Ebola virus is studied and improve our understanding of ...
    (Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
    Breaking Medicine News(10 mins):Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2
    ... small number of teenagers, including non-smokers, are misusing nicotine patches ... could be setting themselves up for health trouble if they ... time or if they use the products to maintain their ... says the students may have lied on the survey. And ...
    ... to Russian universities has picked up after a six ... Medical Council Act in March 2002. ,This was evident ... universities jointly organized by the Russian Cultural Centre and ... to the organisers, at least 235 students had applied ...
    ... lower the risk of pre-eclampsia, doctors say. ,Their review ... women can reduce the risk of perinatal death and ... pre-eclampsia or who had chronic hypertension, diabetes or renal ... to 150 mg) //of aspirin were less likely to ...
    ... to be a better treatment than the antiplatelet drug ... to new research in this week’s issue of the ... black men and women who recently had strokes that ... to blockage of a blood vessel in the brain. ...
    ... kidney transplant patients reduce their risk of heart attacks, ... been shown to minimize cardiovascular disease in people with ... people with normal cholesterol levels who have other conditions ... Kidney transplant patients have a significantly //higher risk of ...
    ... who grow slowly in their first year of life ... true regardless of the socioeconomic status of the child's ... by hampered brain development. Biological processes linked to poor ... function with consequent lower //occupational status and income. ...
    Cached Medicine News:Health News:Teens Misusing Nicotine-Replacement Products 2Health News:Admission to Russian varsities is looking up 2
    ... Counter allows the user to quickly and accurately ... for digital counting or manual counting. An optional ... increasing magnification to 3.0X. The adjustable focusing rod ... or lowered. The lens also rotates a full ...
    The Accucount 2000 is designed to automatically count microscopic objects in a field displaying totals on a highly visible digital readout....
    ... is a Accelerated Bacterial Enumeration System. Bacterial ... of colonies found by the volume dispensed ... A logarithmically decreasing volume of sample is ... Petri dish in an Archimedes spiral. The ...
    ... CEQ 8000 is a fully automated ... the capillary array with a patented linear ... sample, applies the voltage program, and analyzes ... review data quality and even customize automated ...
    Medicine Products: